TNYA
Tenaya Therapeutics, Inc.
Price Chart
Latest Quote
$0.73
+0.02 (+2.68%)
Current Price
| Previous Close | $0.71 |
| Open | $0.71 |
| Day High | $0.74 |
| Day Low | $0.69 |
| Volume | 2,485,336 |
Stock Information
| Shares Outstanding | 217.00M |
| Total Debt | $10.12M |
| Cash Equivalents | $80.89M |
| Revenue | $225K |
| Net Income | $-83.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $158.54M |
| EPS (TTM) | $-0.44 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $76.79M |
| Sales | $225K |
| Income | $-83.00M |
| Book/sh | $0.57 |
| Cash/sh | $0.37 |
| Employees | 70 |
Financial Ratios
| Quick Ratio | 5.45 |
| Current Ratio | 5.75 |
| Debt/Eq | 9.53 |
Returns & Margins
| ROA | -38.46% |
| ROE | -73.59% |
| Gross Margin | 100.00% |
| Operating Margin | -8917.78% |
Ownership
| Insider Ownership | 0.47% |
| Institutional Ownership | 48.38% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.76 |
| P/S | 704.62 |
| P/B | 1.28 |
Analyst Data
| Recommendation | none |
| Target Price | $4.00 |
Technical Indicators
| SMA20 | $0.76 |
| SMA50 | $0.77 |
| SMA200 | $1.01 |
| RSI | 30.17 |
| ATR | 0.0572 |
| Shares Float | 216.07M |
| Short Float | 17.56% |
| Short Ratio | 5.96 |
| Volatility | 2.82 |
| Rel Volume | 0.79 |
Performance History
| Week | +1.53% |
| Month | -7.23% |
| Quarter | -9.08% |
| 6 Months | -4.44% |
| YTD | -0.54% |
| Year | +27.35% |
| 3 Years | -89.75% |
| 10 Years | -95.24% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.73 | 2,551,500 |
| 2026-06-17 | $0.71 | 2,985,600 |
| 2026-06-16 | $0.68 | 3,476,500 |
| 2026-06-15 | $0.72 | 2,131,800 |
| 2026-06-12 | $0.71 | 1,396,200 |
| 2026-06-11 | $0.72 | 2,911,700 |
| 2026-06-10 | $0.70 | 2,063,700 |
| 2026-06-09 | $0.71 | 2,786,300 |
| 2026-06-08 | $0.69 | 4,167,200 |
| 2026-06-05 | $0.73 | 4,521,800 |
| 2026-06-04 | $0.77 | 2,256,700 |
| 2026-06-03 | $0.79 | 5,417,800 |
| 2026-06-02 | $0.79 | 5,650,600 |
| 2026-06-01 | $0.87 | 4,658,900 |
| 2026-05-29 | $0.87 | 5,087,700 |
| 2026-05-28 | $0.80 | 2,685,600 |
| 2026-05-27 | $0.79 | 3,132,100 |
| 2026-05-26 | $0.78 | 2,615,000 |
| 2026-05-22 | $0.77 | 1,627,200 |
| 2026-05-21 | $0.79 | 2,525,900 |
| 2026-05-20 | $0.81 | 1,992,500 |
| 2026-05-19 | $0.79 | 2,957,900 |
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
đ° Latest News
Exploring 3 High Growth Tech Stocks in US Market
Simply Wall St. âĸ 2026-06-15T11:39:04Z
Exploring High Growth Tech Stocks In The US Market
Simply Wall St. âĸ 2026-06-11T11:38:33Z
Exploring 3 High Growth Tech Stocks In The US Market
Simply Wall St. âĸ 2026-06-05T17:38:29Z
US High Growth Tech Stocks with Promising Potential
Simply Wall St. âĸ 2026-06-05T11:38:28Z
High Growth Tech Stocks To Watch In US June 2026
Simply Wall St. âĸ 2026-06-03T11:38:21Z
Top 3 High Growth Tech Stocks in the US Market
Simply Wall St. âĸ 2026-06-01T17:38:46Z
High Growth Tech Stocks in US for May 2026
Simply Wall St. âĸ 2026-05-29T17:38:31Z
US High Growth Tech Stocks To Watch
Simply Wall St. âĸ 2026-05-28T17:38:45Z
Exploring High Growth Tech Stocks In The US Market May 2026
Simply Wall St. âĸ 2026-05-28T11:38:13Z
High Growth US Tech Stocks To Watch In May 2026
Simply Wall St. âĸ 2026-05-27T11:38:21Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $93,331,000 | $115,948,000 | $131,193,000 | $125,621,000 |
| Other Income Expense | $52,000 | $82,000 | $53,000 | $2,000 |
| Other Non Operating Income Expenses | $52,000 | $82,000 | $53,000 | $2,000 |
| Net Non Operating Interest Income Expense | $2,682,000 | $4,737,000 | $7,056,000 | $1,954,000 |
| Operating Expense | $93,331,000 | $115,948,000 | $131,193,000 | $125,621,000 |
| General And Administrative Expense | $24,724,000 | $29,206,000 | $33,155,000 | $31,084,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Net Interest Income | $2,682,000 | $4,737,000 | $7,056,000 | $1,954,000 |
| Interest Income | $2,682,000 | $4,737,000 | $7,056,000 | $1,954,000 |
| Normalized Income | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Net Income From Continuing And Discontinued Operation | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Total Operating Income As Reported | $-93,331,000 | $-115,948,000 | $-131,193,000 | $-125,621,000 |
| Net Income Common Stockholders | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Net Income | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Net Income Including Noncontrolling Interests | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Net Income Continuous Operations | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Pretax Income | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Interest Income Non Operating | $2,682,000 | $4,737,000 | $7,056,000 | $1,954,000 |
| Operating Income | $-93,331,000 | $-115,948,000 | $-131,193,000 | $-125,621,000 |
| Per Share | ||||
| Diluted EPS | $-0.59 | $-1.31 | $-1.68 | $-2.76 |
| Basic EPS | $-0.59 | $-1.31 | $-1.68 | $-2.76 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-84,895,000 | $-107,480,000 | $-122,506,000 | $-119,154,000 |
| Reconciled Depreciation | $8,436,000 | $8,468,000 | $8,687,000 | $6,467,000 |
| EBITDA (Bullshit earnings) | $-84,895,000 | $-107,480,000 | $-122,506,000 | $-119,154,000 |
| EBIT | $-93,331,000 | $-115,948,000 | $-131,193,000 | $-125,621,000 |
| Diluted Average Shares | $152,971,259 | $84,822,468 | $73,786,126 | $44,823,597 |
| Basic Average Shares | $152,971,259 | $84,822,468 | $73,786,126 | $44,823,597 |
| Diluted NI Availto Com Stockholders | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Research And Development | $68,607,000 | $86,742,000 | $98,038,000 | $94,537,000 |
| Selling General And Administration | $24,724,000 | $29,206,000 | $33,155,000 | $31,084,000 |
| Other Gand A | $24,724,000 | $29,206,000 | $33,155,000 | $31,084,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $123,265,000 | $92,854,000 | $139,424,000 | $243,376,000 |
| Total Assets | $146,921,000 | $119,940,000 | $170,515,000 | $278,945,000 |
| Total Non Current Assets | $41,335,000 | $52,565,000 | $58,933,000 | $85,191,000 |
| Other Non Current Assets | $4,246,000 | $4,817,000 | $5,677,000 | $4,793,000 |
| Current Assets | $105,586,000 | $67,375,000 | $111,582,000 | $193,754,000 |
| Other Current Assets | $1,025,000 | $842,000 | $1,157,000 | $938,000 |
| Prepaid Assets | $4,014,000 | $5,087,000 | $5,783,000 | $4,044,000 |
| Cash Cash Equivalents And Short Term Investments | $100,547,000 | $61,446,000 | $104,642,000 | $186,527,000 |
| Cash And Cash Equivalents | $100,547,000 | $4,323,000 | $45,681,000 | $95,272,000 |
| Investmentin Financial Assets | - | - | $0 | $17,703,000 |
| Receivables | - | - | $0 | $2,245,000 |
| Taxes Receivable | - | - | $0 | $2,245,000 |
| Debt | ||||
| Total Debt | $10,830,000 | $13,608,000 | $12,424,000 | $15,099,000 |
| Long Term Debt And Capital Lease Obligation | $7,810,000 | $10,830,000 | $8,105,000 | $11,093,000 |
| Current Debt And Capital Lease Obligation | $3,020,000 | $2,778,000 | $4,319,000 | $4,006,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $23,656,000 | $27,086,000 | $31,091,000 | $35,569,000 |
| Total Non Current Liabilities Net Minority Interest | $8,220,000 | $11,111,000 | $8,358,000 | $11,321,000 |
| Other Non Current Liabilities | $410,000 | $281,000 | $253,000 | $228,000 |
| Current Liabilities | $15,436,000 | $15,975,000 | $22,733,000 | $24,248,000 |
| Other Current Liabilities | $176,000 | $214,000 | $478,000 | $545,000 |
| Payables And Accrued Expenses | $6,227,000 | $7,388,000 | $9,236,000 | $13,274,000 |
| Payables | $3,858,000 | $5,510,000 | $5,910,000 | $9,578,000 |
| Total Tax Payable | $277,000 | $348,000 | $280,000 | - |
| Accounts Payable | $3,581,000 | $5,162,000 | $5,630,000 | $9,578,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $123,265,000 | $92,854,000 | $139,424,000 | $243,376,000 |
| Total Equity Gross Minority Interest | $123,265,000 | $92,854,000 | $139,424,000 | $243,376,000 |
| Stockholders Equity | $123,265,000 | $92,854,000 | $139,424,000 | $243,376,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $28,000 | $-106,000 | $-378,000 |
| Retained Earnings | $-605,008,000 | $-514,411,000 | $-403,282,000 | $-279,198,000 |
| Other Equity Adjustments | - | $28,000 | $-106,000 | $-378,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $216,760,283 | $86,542,340 | $68,330,342 | $66,857,113 |
| Share Issued | $216,760,283 | $86,542,340 | $68,330,342 | $66,857,113 |
| Tangible Book Value | $123,265,000 | $92,854,000 | $139,424,000 | $243,376,000 |
| Invested Capital | $123,265,000 | $92,854,000 | $139,424,000 | $243,376,000 |
| Working Capital | $90,150,000 | $51,400,000 | $88,849,000 | $169,506,000 |
| Capital Lease Obligations | $10,830,000 | $13,608,000 | $12,424,000 | $15,099,000 |
| Total Capitalization | $123,265,000 | $92,854,000 | $139,424,000 | $243,376,000 |
| Additional Paid In Capital | $728,252,000 | $607,229,000 | $542,805,000 | $522,945,000 |
| Capital Stock | $21,000 | $8,000 | $7,000 | $7,000 |
| Common Stock | $21,000 | $8,000 | $7,000 | $7,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $7,810,000 | $10,830,000 | $8,105,000 | $11,093,000 |
| Current Capital Lease Obligation | $3,020,000 | $2,778,000 | $4,319,000 | $4,006,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,013,000 | $5,595,000 | $8,700,000 | $6,423,000 |
| Current Accrued Expenses | $2,369,000 | $1,878,000 | $3,326,000 | $3,696,000 |
| Net PPE | $37,089,000 | $47,748,000 | $53,256,000 | $62,695,000 |
| Accumulated Depreciation | $-39,933,000 | $-32,290,000 | $-24,340,000 | $-15,676,000 |
| Gross PPE | $77,022,000 | $80,038,000 | $77,596,000 | $78,371,000 |
| Leases | $26,244,000 | $26,159,000 | $25,608,000 | $23,605,000 |
| Construction In Progress | $67,000 | $1,915,000 | $1,730,000 | $3,128,000 |
| Other Properties | $28,431,000 | $31,660,000 | $29,952,000 | $32,200,000 |
| Machinery Furniture Equipment | $22,280,000 | $20,304,000 | $20,306,000 | $19,438,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $57,123,000 | $58,961,000 | $91,255,000 |
| Treasury Shares Number | - | - | $0 | - |
| Investments And Advances | - | - | $0 | $17,703,000 |
| Available For Sale Securities | - | - | - | $17,703,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-68,882,000 | $-91,526,000 | $-103,311,000 | $-125,054,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-68,264,000 | $-90,501,000 | $-102,072,000 | $-104,424,000 |
| Cash Flow From Continuing Operating Activities | $-68,264,000 | $-90,501,000 | $-102,072,000 | $-104,424,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-618,000 | $-1,025,000 | $-1,239,000 | $-20,630,000 |
| Investing Cash Flow | $56,083,000 | $1,131,000 | $48,715,000 | $83,652,000 |
| Cash Flow From Continuing Investing Activities | $56,083,000 | $1,131,000 | $48,715,000 | $83,652,000 |
| Net Other Investing Changes | - | $17,000 | $-25,000 | $8,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $105,977,000 | $46,762,000 | $3,868,000 | $77,387,000 |
| Financing Cash Flow | $108,405,000 | $47,749,000 | $4,049,000 | $77,767,000 |
| Cash Flow From Continuing Financing Activities | $108,405,000 | $47,749,000 | $4,049,000 | $77,767,000 |
| Net Common Stock Issuance | $105,977,000 | $46,762,000 | $3,868,000 | $77,387,000 |
| Common Stock Issuance | $105,977,000 | $46,762,000 | $3,868,000 | $77,387,000 |
| Net Other Financing Charges | - | - | $-501,000 | - |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $100,966,000 | $4,742,000 | $46,363,000 | $95,671,000 |
| Beginning Cash Position | $4,742,000 | $46,363,000 | $95,671,000 | $38,676,000 |
| Changes In Cash | $96,224,000 | $-41,621,000 | $-49,308,000 | $56,995,000 |
| Proceeds From Stock Option Exercised | $2,428,000 | $987,000 | $682,000 | $380,000 |
| Net Investment Purchase And Sale | $56,701,000 | $2,139,000 | $49,979,000 | $104,274,000 |
| Sale Of Investment | $56,701,000 | $89,208,000 | $106,623,000 | $244,750,000 |
| Purchase Of Investment | $0 | $-87,069,000 | $-56,644,000 | $-140,476,000 |
| Net PPE Purchase And Sale | $-618,000 | $-1,025,000 | $-1,239,000 | $-20,630,000 |
| Purchase Of PPE | $-618,000 | $-1,025,000 | $-1,239,000 | $-20,630,000 |
| Change In Working Capital | $-2,456,000 | $-7,931,000 | $-5,648,000 | $-849,000 |
| Change In Other Current Liabilities | $-2,676,000 | $-4,118,000 | $-4,122,000 | $-3,108,000 |
| Change In Other Current Assets | $571,000 | $656,000 | $-601,000 | $-815,000 |
| Change In Payables And Accrued Expense | $-898,000 | $-5,326,000 | $-1,026,000 | $6,008,000 |
| Change In Accrued Expense | $532,000 | $-4,745,000 | $2,256,000 | $4,348,000 |
| Change In Payable | $-1,430,000 | $-581,000 | $-3,282,000 | $1,660,000 |
| Change In Account Payable | $-1,430,000 | $-581,000 | $-3,282,000 | $1,660,000 |
| Change In Prepaid Assets | $547,000 | $857,000 | $101,000 | $-2,934,000 |
| Other Non Cash Items | $2,896,000 | $3,774,000 | $3,349,000 | $2,463,000 |
| Stock Based Compensation | $13,046,000 | $16,501,000 | $15,309,000 | $11,467,000 |
| Amortization Of Securities | $411,000 | $-184,000 | $315,000 | $-307,000 |
| Depreciation Amortization Depletion | $8,436,000 | $8,468,000 | $8,687,000 | $6,467,000 |
| Depreciation And Amortization | $8,436,000 | $8,468,000 | $8,687,000 | $6,467,000 |
| Net Income From Continuing Operations | $-90,597,000 | $-111,129,000 | $-124,084,000 | $-123,665,000 |
| Depreciation | - | $8,468,000 | $8,687,000 | $6,467,000 |
| Common Stock Payments | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-20